Literature DB >> 12527583

Lung cancer. Special treatment issues.

Frank C Detterbeck1, David R Jones, Kemp H Kernstine, Keith S Naunheim.   

Abstract

This chapter of the Lung Cancer Guidelines addresses patients with particular forms of non-small cell lung cancer that require special considerations. This includes patients with Pancoast tumors, T4N0,1M0 tumors, satellite nodules in the same lobe, synchronous and metachronous multiple primary lung cancers (MPLC), and solitary metastases. For patients with a Pancoast tumor, a multimodality approach, involving chemoradiotherapy and surgical resection, appears optimal provided appropriate staging has been carried out. Patients with central T4 tumors that do not have mediastinal node involvement are uncommon. When carefully staged and selected, however, such patients appear to benefit from resection as part of the treatment as opposed to chemoradiotherapy alone. Patients with a satellite lesion in the same lobe as the primary tumor have a good prognosis and require no modification of the approach to evaluation and treatment from what would be dictated by the primary tumor alone. On the other hand, it is difficult to know how best to treat patients with a focus of the same type of cancer in a different lobe. Although MPLC do occur, the survival results after resection for either a synchronous presentation or a metachronous presentation with an interval of < 4 years between tumors are variable and generally poor, suggesting that many of these patients may have had a pulmonary metastasis rather than a second primary lung cancer. A thorough and careful evaluation of these patients is warranted to try to differentiate between patients with a metastasis and those with a second primary lung cancer, although criteria to distinguish them have not been defined. Finally, some patients with a solitary focus of metastatic disease in the brain or adrenal gland appear to benefit substantially from resection.

Entities:  

Mesh:

Year:  2003        PMID: 12527583     DOI: 10.1378/chest.123.1_suppl.244s

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  24 in total

1.  Trimodality therapy for superior sulcus non-small cell lung cancer: Southwest Oncology Group-Intergroup Trial S0220.

Authors:  Kemp H Kernstine; James Moon; Michael J Kraut; Katherine M W Pisters; Joshua R Sonett; Valerie W Rusch; Charles R Thomas; Thomas K Waddell; James R Jett; Alan P Lyss; Steven M Keller; David R Gandara
Journal:  Ann Thorac Surg       Date:  2014-06-28       Impact factor: 4.330

2.  Low dose non-enhanced CT versus standard dose contrast-enhanced CT in combined PET/CT protocols for staging and therapy planning in non-small cell lung cancer.

Authors:  Anna C Pfannenberg; Philip Aschoff; Klaus Brechtel; Mark Müller; Roland Bares; Frank Paulsen; Jutta Scheiderbauer; Godehard Friedel; Claus D Claussen; Susanne M Eschmann
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-08-01       Impact factor: 9.236

3.  Survival rate and prognostic factors of surgically resected clinically synchronous multiple primary non-small cell lung cancer and further differentiation from intrapulmonary metastasis.

Authors:  Fei Xiao; Deruo Liu; Yongqing Guo; Bin Shi; Zhiyi Song; Yanchu Tian; Zhenrong Zhang; Chaoyang Liang
Journal:  J Thorac Dis       Date:  2017-04       Impact factor: 2.895

4.  Establishing a TNM-like risk classification for metachronous second pulmonary adenocarcinoma in patients with previously resected pulmonary adenocarcinoma.

Authors:  Shen-Shen Fu; Yu-Zhen Zheng; Xian-Yu Qin; Xing-Ping Yang; Piao Shen; Wei-Jie Cai; Xiao-Qiang Li; Hong-Ying Liao
Journal:  J Thorac Dis       Date:  2022-05       Impact factor: 3.005

5.  Synchronous double primary lung cancer: a report of three cases.

Authors:  Xue-Dong Liu; Yan Qu; Sen-Sen Lu
Journal:  Chin J Cancer Res       Date:  2014-02       Impact factor: 5.087

6.  A patient with four-year survival after nonsmall cell lung carcinoma with a solitary metachronous small bowel metastasis.

Authors:  Klaas M Kant; Vincent Noordhoek Hegt; Joachim G J V Aerts
Journal:  J Oncol       Date:  2010-03-07       Impact factor: 4.375

7.  Prognosis associated with surgery for non-small cell lung cancer and synchronous brain metastasis.

Authors:  Takashi Kanou; Jiro Okami; Toshiteru Tokunaga; Ayako Fujiwara; Daisuke Ishida; Hidenori Kuno; Masahiko Higashiyama
Journal:  Surg Today       Date:  2014-04-20       Impact factor: 2.549

8.  [Research Progress in Distinguishing Methods of Simultaneous Multiple Primary Lung Cancer and Intrapulmonary Metastasis].

Authors:  Jifan Wang; Te Zhang; Hanlin Ding; Gaochao Dong; Lin Xu; Feng Jiang
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2021-05-20

9.  Molecular Identification and Genetic Characterization of Early-Stage Multiple Primary Lung Cancer by Large-Panel Next-Generation Sequencing Analysis.

Authors:  Guotian Pei; Mingwei Li; Xianjun Min; Qiang Liu; Dasheng Li; Yingshun Yang; Shuai Wang; Xiaoyu Wang; Huina Wang; Huanqing Cheng; Shanbo Cao; Yuqing Huang
Journal:  Front Oncol       Date:  2021-05-24       Impact factor: 6.244

10.  Bevacizumab: the evidence for its clinical potential in the treatment of nonsmall cell lung cancer.

Authors:  Sonya Haslam; Paul Chrisp
Journal:  Core Evid       Date:  2007-03-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.